Neutral sphingomyelinase-2 deficiency ameliorates Alzheimer’s disease pathology and improves cognition in the 5XFAD mouse

Michael B. Dinkins, John Enasko, Caterina M. Hernandez, Guanghu Wang, Jina Kong, Inas Helwa, Yutao Liu, Alvin V Terry, Erhard Bieberich

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Recent evidence implicates exosomes in the aggregation of Aβ and spreading of tau in Alzheimer’s disease. In neural cells, exosome formation can be blocked by inhibition or silencing of neutral sphingomyelinase-2 (nSMase2). We generated genetically nSMase2- deficient 5XFAD mice (fro;5XFAD) to assess AD-related pathology in a mouse model with consistently reduced ceramide generation. We conducted in vitro assays to assess Aβ42 aggregation and glial clearance with and without exosomes isolated by ultracentrifugation and determined exosome-induced amyloid aggregation by particle counting.Weanalyzed brain exosome content, amyloid plaque formation, neuronal degeneration, sphingolipid, Aβ42 and phospho-tau levels, and memory-related behaviors in 5XFAD versus fro;5XFAD mice using contextual and cued fear conditioning. Astrocyte-derived exosomes accelerated aggregation of Aβ42 and blocked glial clearance of Aβ42 in vitro. Aβ42 aggregates were colocalized with extracellular ceramide in vitro using a bifunctional ceramide analog preloaded into exosomes and in vivo using anticeramide IgG, implicating ceramide-enriched exosomes in plaque formation. Compared with 5XFAD mice, the fro;5XFAD mice had reduced brain exosomes, ceramide levels, serum anticeramide IgG, glial activation, total Aβ42 and plaque burden, tau phosphorylation, and improved cognition in a fear-conditioned learning task. Ceramide-enriched exosomes appear to exacerbate AD-related brain pathology by promoting the aggregation of Aβ. Reduction of exosome secretion by nSMase2 loss of function improves pathology and cognition in the 5XFAD mouse model.

Original languageEnglish (US)
Pages (from-to)8653-8667
Number of pages15
JournalJournal of Neuroscience
Volume36
Issue number33
DOIs
StatePublished - Aug 17 2016

Fingerprint

Type A Niemann-Pick Disease
Exosomes
Cognition
Alzheimer Disease
Pathology
Ceramides
Sphingomyelin Phosphodiesterase
Neuroglia
Fear
Brain
Immunoglobulin G
Sphingolipids
Ultracentrifugation
Amyloid Plaques
Amyloid
Astrocytes

Keywords

  • 5XFAD
  • Alzheimer’s
  • Ceramide
  • Exosomes
  • Fear conditioning
  • Sphingomyelinase

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Neutral sphingomyelinase-2 deficiency ameliorates Alzheimer’s disease pathology and improves cognition in the 5XFAD mouse. / Dinkins, Michael B.; Enasko, John; Hernandez, Caterina M.; Wang, Guanghu; Kong, Jina; Helwa, Inas; Liu, Yutao; Terry, Alvin V; Bieberich, Erhard.

In: Journal of Neuroscience, Vol. 36, No. 33, 17.08.2016, p. 8653-8667.

Research output: Contribution to journalArticle

Dinkins, Michael B. ; Enasko, John ; Hernandez, Caterina M. ; Wang, Guanghu ; Kong, Jina ; Helwa, Inas ; Liu, Yutao ; Terry, Alvin V ; Bieberich, Erhard. / Neutral sphingomyelinase-2 deficiency ameliorates Alzheimer’s disease pathology and improves cognition in the 5XFAD mouse. In: Journal of Neuroscience. 2016 ; Vol. 36, No. 33. pp. 8653-8667.
@article{8349fea0c4b84c089aacfca9afab757e,
title = "Neutral sphingomyelinase-2 deficiency ameliorates Alzheimer’s disease pathology and improves cognition in the 5XFAD mouse",
abstract = "Recent evidence implicates exosomes in the aggregation of Aβ and spreading of tau in Alzheimer’s disease. In neural cells, exosome formation can be blocked by inhibition or silencing of neutral sphingomyelinase-2 (nSMase2). We generated genetically nSMase2- deficient 5XFAD mice (fro;5XFAD) to assess AD-related pathology in a mouse model with consistently reduced ceramide generation. We conducted in vitro assays to assess Aβ42 aggregation and glial clearance with and without exosomes isolated by ultracentrifugation and determined exosome-induced amyloid aggregation by particle counting.Weanalyzed brain exosome content, amyloid plaque formation, neuronal degeneration, sphingolipid, Aβ42 and phospho-tau levels, and memory-related behaviors in 5XFAD versus fro;5XFAD mice using contextual and cued fear conditioning. Astrocyte-derived exosomes accelerated aggregation of Aβ42 and blocked glial clearance of Aβ42 in vitro. Aβ42 aggregates were colocalized with extracellular ceramide in vitro using a bifunctional ceramide analog preloaded into exosomes and in vivo using anticeramide IgG, implicating ceramide-enriched exosomes in plaque formation. Compared with 5XFAD mice, the fro;5XFAD mice had reduced brain exosomes, ceramide levels, serum anticeramide IgG, glial activation, total Aβ42 and plaque burden, tau phosphorylation, and improved cognition in a fear-conditioned learning task. Ceramide-enriched exosomes appear to exacerbate AD-related brain pathology by promoting the aggregation of Aβ. Reduction of exosome secretion by nSMase2 loss of function improves pathology and cognition in the 5XFAD mouse model.",
keywords = "5XFAD, Alzheimer’s, Ceramide, Exosomes, Fear conditioning, Sphingomyelinase",
author = "Dinkins, {Michael B.} and John Enasko and Hernandez, {Caterina M.} and Guanghu Wang and Jina Kong and Inas Helwa and Yutao Liu and Terry, {Alvin V} and Erhard Bieberich",
year = "2016",
month = "8",
day = "17",
doi = "10.1523/JNEUROSCI.1429-16.2016",
language = "English (US)",
volume = "36",
pages = "8653--8667",
journal = "Journal of Neuroscience",
issn = "0270-6474",
publisher = "Society for Neuroscience",
number = "33",

}

TY - JOUR

T1 - Neutral sphingomyelinase-2 deficiency ameliorates Alzheimer’s disease pathology and improves cognition in the 5XFAD mouse

AU - Dinkins, Michael B.

AU - Enasko, John

AU - Hernandez, Caterina M.

AU - Wang, Guanghu

AU - Kong, Jina

AU - Helwa, Inas

AU - Liu, Yutao

AU - Terry, Alvin V

AU - Bieberich, Erhard

PY - 2016/8/17

Y1 - 2016/8/17

N2 - Recent evidence implicates exosomes in the aggregation of Aβ and spreading of tau in Alzheimer’s disease. In neural cells, exosome formation can be blocked by inhibition or silencing of neutral sphingomyelinase-2 (nSMase2). We generated genetically nSMase2- deficient 5XFAD mice (fro;5XFAD) to assess AD-related pathology in a mouse model with consistently reduced ceramide generation. We conducted in vitro assays to assess Aβ42 aggregation and glial clearance with and without exosomes isolated by ultracentrifugation and determined exosome-induced amyloid aggregation by particle counting.Weanalyzed brain exosome content, amyloid plaque formation, neuronal degeneration, sphingolipid, Aβ42 and phospho-tau levels, and memory-related behaviors in 5XFAD versus fro;5XFAD mice using contextual and cued fear conditioning. Astrocyte-derived exosomes accelerated aggregation of Aβ42 and blocked glial clearance of Aβ42 in vitro. Aβ42 aggregates were colocalized with extracellular ceramide in vitro using a bifunctional ceramide analog preloaded into exosomes and in vivo using anticeramide IgG, implicating ceramide-enriched exosomes in plaque formation. Compared with 5XFAD mice, the fro;5XFAD mice had reduced brain exosomes, ceramide levels, serum anticeramide IgG, glial activation, total Aβ42 and plaque burden, tau phosphorylation, and improved cognition in a fear-conditioned learning task. Ceramide-enriched exosomes appear to exacerbate AD-related brain pathology by promoting the aggregation of Aβ. Reduction of exosome secretion by nSMase2 loss of function improves pathology and cognition in the 5XFAD mouse model.

AB - Recent evidence implicates exosomes in the aggregation of Aβ and spreading of tau in Alzheimer’s disease. In neural cells, exosome formation can be blocked by inhibition or silencing of neutral sphingomyelinase-2 (nSMase2). We generated genetically nSMase2- deficient 5XFAD mice (fro;5XFAD) to assess AD-related pathology in a mouse model with consistently reduced ceramide generation. We conducted in vitro assays to assess Aβ42 aggregation and glial clearance with and without exosomes isolated by ultracentrifugation and determined exosome-induced amyloid aggregation by particle counting.Weanalyzed brain exosome content, amyloid plaque formation, neuronal degeneration, sphingolipid, Aβ42 and phospho-tau levels, and memory-related behaviors in 5XFAD versus fro;5XFAD mice using contextual and cued fear conditioning. Astrocyte-derived exosomes accelerated aggregation of Aβ42 and blocked glial clearance of Aβ42 in vitro. Aβ42 aggregates were colocalized with extracellular ceramide in vitro using a bifunctional ceramide analog preloaded into exosomes and in vivo using anticeramide IgG, implicating ceramide-enriched exosomes in plaque formation. Compared with 5XFAD mice, the fro;5XFAD mice had reduced brain exosomes, ceramide levels, serum anticeramide IgG, glial activation, total Aβ42 and plaque burden, tau phosphorylation, and improved cognition in a fear-conditioned learning task. Ceramide-enriched exosomes appear to exacerbate AD-related brain pathology by promoting the aggregation of Aβ. Reduction of exosome secretion by nSMase2 loss of function improves pathology and cognition in the 5XFAD mouse model.

KW - 5XFAD

KW - Alzheimer’s

KW - Ceramide

KW - Exosomes

KW - Fear conditioning

KW - Sphingomyelinase

UR - http://www.scopus.com/inward/record.url?scp=84982298737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982298737&partnerID=8YFLogxK

U2 - 10.1523/JNEUROSCI.1429-16.2016

DO - 10.1523/JNEUROSCI.1429-16.2016

M3 - Article

VL - 36

SP - 8653

EP - 8667

JO - Journal of Neuroscience

JF - Journal of Neuroscience

SN - 0270-6474

IS - 33

ER -